Best Practice & Research Clinical Haematology
Volume 19, Issue 2 , Pages 333-339 , June 2006

Hematopoietic cell transplantation in first complete remission versus early relapse

  • Frederick R. Appelbaum, MD (Director)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 206 667 4412; Fax: +1 206 667 6936.
  • S. Frieda Pearce, PhD

      Affiliations

    • Dr Pearce prepared the first draft of the manuscript based on slides and a transcript of a talk given by Dr Appelbaum.

References 

  1. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European organization for research and treatment of cancer (EORTC) and the gruppo italiano malattie ematologiche maligne dell'adulto (GIMEMA) leukemia cooperative groups. New England Journal of Medicine. 1995;332:217–223
  2. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK medical research council adult and children's leukaemia working parties. Lancet. 1998;351:700–708
  3. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The groupe ouest est leucemies aigues myeloblastiques (GOELAM). Blood. 1997;90:2978–2986
  4. Tallman MS, Kopecky KJ, Amos D, et al. Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission. Journal of Clinical Oncology. 1989;7:326–337
  5. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative, Oncology Group study. Blood. 2000;96:4075–4083
  6. Willemze R, Suciu S, Mandelli F, et al. Autologous versus allogeneic stem cell transplantation in acute myeloid leukemia. Annals of Hematology. 2004;83(supplement 1):S134
  7. http://www.ibmtr.org
  8. Gale RP, Horowitz MM, Rees JK, et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia. 1996;10:13–19
  9. Appelbaum FR, Clift RA, Buckner CD, et al. Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. Blood. 1983;61:949–953
  10. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. Journal of Clinical Oncology. 1992;10:1723–1729
  11. Schiffman K, Clift R, Appelbaum FR, et al. Consequences of cryopreserving first remission autologous marrow for use after relapse in patients with acute myeloid leukemia. Bone Marrow Transplantation. 1993;11:227–232
  12. Brown RA, Wolff SN, Fay JW, et al. High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American marrow transplant group. Blood. 1995;85:1391–1395
  13. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100:1611–1618
  14. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. New England Journal of Medicine. 2004;351:2265–2275
  15. Appelbaum FR. Allogeneic hematopoietic stem cell transplantation for acute leukemia. Seminars in Oncology. 1997;24:114–123
  16. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102:1232–1240
  17. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. New England Journal Medicine. 1998;339:1649–1656

PII: S1521-6926(05)00124-6

doi: 10.1016/j.beha.2005.12.001

Best Practice & Research Clinical Haematology
Volume 19, Issue 2 , Pages 333-339 , June 2006

Article Tools

* Image Usage & Resolution